Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

Peer Review reports

Original Submission
24 Feb 2022	Submitted	Original manuscript
4 Mar 2022	Reviewed	Reviewer Report
10 Mar 2022	Reviewed	Reviewer Report - Ling-xiao Liu
17 Mar 2022	Author responded	Author comments - Bin Xiong
Resubmission - Version 2
17 Mar 2022	Submitted	Manuscript version 2
Publishing
22 Mar 2022	Editorially accepted
27 Mar 2022	Article published	10.1186/s12885-022-09451-1

Back to article page